Rezolute says cash position totals $120 million, funds operations into mid-2028 - RZLT News | RalliesRezolute says cash position totals $120 million, funds operations into mid-2028
R
RZLT• Company update and clinical program status
- Rezolute highlighted ersodetug, an IV monoclonal antibody targeting the insulin receptor for refractory hypoglycemia across hyperinsulinism types.
- Phase 3 sunRIZE in congenital hyperinsulinism completed; open-label extension ongoing with 100% rollover and high retention.
- Primary SMBG endpoint missed due to functional unblinding; multiple CGM measures showed clinically meaningful hypoglycemia reductions.
- FDA review of analysis datasets ongoing; program update expected in 2H 2026, with topline data targeted for Q1 2027.
- Cash position cited at USD 120 million, with runway to mid-2028; company framed a USD 1 billion-plus global market opportunity.
•
